Page 40 - Read Online

Piñeiro et al. J Cancer Metastasis Treat 2021;7:10 I http://dx.doi.org/10.20517/2394-4722.2020.115 Page 11 of 13

4. Coccia M. Factors determining the diffusion of COVID-19 and suggested strategy to prevent future accelerated viral infectivity similar to
COVID. Sci Total Environ 2020;729:138474.
5. Coccia M. An index to quantify environmental risk of exposure to future epidemics of the COVID-19 and similar viral agents: Theory
and practice. Environ Res 2020;191:110155.
6. Rosario DKA, Mutz YS, Bernardes PC, Conte-Junior CA. Relationship between COVID-19 and weather: case study in a tropical country.
Int J Hyg Environ Health 2020;229:113587.
7. Bashir MF, Ma BJ, Bilal, et al. Correlation between environmental pollution indicators and COVID-19 pandemic: A brief study in
Californian context. Environ Res 2020;187:109652.
8. International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC). COVID-19 Report: 19 May 2020 [Internet]:
ISARIC; 2020. Available from: https://media.tghn.org/medialibrary/2020/05/ISARIC_Data_Platform_COVID-19_Report_19MAY20.
pdf. [Last accesses on 2 Feb 2021]
9. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19-
Preliminary Report. N Engl J Med 2020;17:NEJMoa2021436.
10. National Institutes of Health (NIH). The National Institutes of Health COVID-19 Treatment Guidelines Panel Provides Recommendations
for Dexamethasone in Patients with COVID-19 [Internet]. NIH; 2020 [updated 25 June 2020; cited 29 June 2020]. Available from: https://
www.covid19treatmentguidelines.nih.gov/dexamethasone/ [Last accesses on 2 Feb 2021]
11. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med 2020;383:1813-26.
12. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate
COVID-19: a randomized clinical trial. JAMA 2020;324:1048-57.
13. Fda.com (Internet). United Stated Food and Drug Administration (FDA) c2020 (cited Dec 6th 2020). Available from: https://www.fda.
gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
14. World Health Organization (WHO). “Solidarity” clinical trial for COVID-19 treatments. Geneva: WHO; 2020 [cited 22 July 2020].
Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/
solidarity-clinical-trial-for-covid-19-treatments. [Last accesses on 2 Feb 2021]
15. Randomised Evaluation of COVid-19 Therapy (RECOVERY) Trial. No clinical benefit from use of hydroxychloroquine inhospitalised
patients with COVID-19: Nuffield Department of Population Health University of Oxford; 2020 [updated 5 June 2020]. Available from:
https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-
trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19.
[Last accesses on 2 Feb 2021]
16. Cao B, Wang Y, Wen D, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382:1787-99.
17. European Commission-Directorate-General For Health And Food Safety. An EU programme of COVID-19 convalescent plasma
collection and transfusion. Guidance on collection, testing, processing, storage, distribution and monitored use. 2020. Available from:
https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf. [Last accesses on 2 Feb 2021]
18. Draft landscape of COVID-19 candidate vaccines. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-
candidate-vaccines [Last accesses on 2 Feb 2021]
19. Rogado J, Obispo B, Pangua C, et al. Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of
the pandemic in a Spanish hospital in Madrid. Clin Transl Oncol 2020;22:2364-8.
20. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA
Oncol 2020;6:1108-10.
21. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335-7
22. Giannakoulis VG, Papoutsi E, Siempos II. Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient
data. JCO Glob Oncol 2020;6:799-808
23. Venkatesulu BP, Chandrasekar VT, Girdhar P, et al. A systematic review and meta-analysis of cancer patients affected by a novel
coronavirus. Preprint. medRxiv. 2020;2020.05.27.20115303.
24. Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in
Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020;21:893-903.
25. Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19
outbreak. Cancer Discov 2020;10:783-91.
26. Jee J, Foote MB, Lumish M, et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol 2020;38: 3538-46.
27. Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov
2020;10:935-41.
28. Rogado J, Pangua C, Serrano-Montero G, et al. Covid-19 and lung cancer: a greater fatality rate? Lung Cancer 2020;146:19-22.
29. Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19
(COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 2020;34:327-31.
30. Zhang Y, Zhong Y, Pan L, Dong J. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: are we already that far? Drug Discov
Ther 2020;14:100-2.
31. Dai MY, Chen Z, Leng Y, et al. Patients with lung cancer have high susceptibility of COVID-19: a retrospective study in Wuhan, China.
Cancer Control 2020;27:1073274820960467.
32. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020;92:814-8.
33. David E, Mifthun MD. Overview of the initial treatment and prognosis of lung cancer. UptoDate. [Last accesses on 2 Feb 2021]